BTG appoints non-exec director
This article was originally published in Scrip
BTG, a specialist healthcare company developing and commercializing products targeting critical care, cancer and other disorders, has named Susan Foden a non-executive director of its board – effective 1 March 2015. Dr Foden is currently chair of BerGenBio and Cizzle Biotech, holds non-executive roles with Vectura Group, Evgen and Source Bioscience and is an advisory board member for CD3 (a joint initiative between Leuven University and the European Investment Fund). Previously Dr Foden has held the positions of investor director with the venture capital firm Merlin Biosciences, CEO of the technology transfer company Cancer Research Campaign Technology, and head of academic liaison at Celltech.